Title: Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
Abstract:Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen rece...Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance to androgen deprivation therapy is inevitable. After using enzalutamide, the first new generation anti-androgen (AA), two new generation AA drugs were synthesized. New generation anti-androgen drugs are used especially in castration resistance prostate cancer. But recently, there are new publications regarding using new generation anti-androgens in castration sensitive prostate cancer patients. In this review, we will compare structure, mechanisms of effect and clinical outcomes in phase 3 trials of these new generation AA drugs.Read More